These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 19996582

  • 1. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H.
    Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
    [Abstract] [Full Text] [Related]

  • 2. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, Fürst S, Ziegler SI, Brohl F, Schwaiger M, Scheidhauer K.
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [Abstract] [Full Text] [Related]

  • 4. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
    Schiesser M, Veit-Haibach P, Muller MK, Weber M, Bauerfeind P, Hany T, Clavien PA.
    Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
    [Abstract] [Full Text] [Related]

  • 5. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
    Steffen IG, Mehl S, Heuck F, Elgeti F, Furth C, Amthauer H, Ruf J.
    Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
    [Abstract] [Full Text] [Related]

  • 6. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V, Röttgen R, Collettini F, Rothe J, Hamm B, Brenner W, Schreiter N.
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [Abstract] [Full Text] [Related]

  • 7. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 8. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 9. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE.
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol.
    Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, Denecke T, Pavel M, Pascher A, Wiedenmann B, Amthauer H.
    J Nucl Med; 2011 May; 52(5):697-704. PubMed ID: 21498531
    [Abstract] [Full Text] [Related]

  • 11. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y, Sano K, Ishimori T, Ueda M, Temma T, Saji H, Togashi K.
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [Abstract] [Full Text] [Related]

  • 12. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ, Zhang YX, Wei H, Jia Q.
    Zhonghua Yi Xue Za Zhi; 2007 Aug 28; 87(32):2253-6. PubMed ID: 18001544
    [Abstract] [Full Text] [Related]

  • 13. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
    Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, Brendle C, Werner MK, Claussen CD, Pfannenberg C.
    Cancer Imaging; 2013 Mar 05; 13(1):63-72. PubMed ID: 23466785
    [Abstract] [Full Text] [Related]

  • 14. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.
    Giesel FL, Kratochwil C, Mehndiratta A, Wulfert S, Moltz JH, Zechmann CM, Kauczor HU, Haberkorn U, Ley S.
    Eur J Radiol; 2012 Oct 05; 81(10):2820-5. PubMed ID: 22236704
    [Abstract] [Full Text] [Related]

  • 15. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H, Rosenbaum-Krumme S, Veit-Haibach P, Stergar H, Forsting M, Bockisch A, Antoch G.
    Nucl Med Commun; 2008 Jul 05; 29(7):599-606. PubMed ID: 18528181
    [Abstract] [Full Text] [Related]

  • 16. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M, Ardissone F.
    Eur J Cardiothorac Surg; 2009 Sep 05; 36(3):440-5. PubMed ID: 19464906
    [Abstract] [Full Text] [Related]

  • 17. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD, Veit-Haibach P, Strobel K, Breitenstein S, Tschopp A, Mende KA, Lago MP, Hany TF.
    J Nucl Med; 2008 Mar 05; 49(3):354-61. PubMed ID: 18287263
    [Abstract] [Full Text] [Related]

  • 18. Incidental PET/CT findings in the cancer patient: how should they be managed?
    Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM.
    Surgery; 2009 Aug 05; 146(2):274-81. PubMed ID: 19628085
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
    Cwikla JB, Nasierowska-Guttmejer A, Jeziorski KG, Cichocki A, Zgliczynski W, Stepień K, Seklecka N, Durlik M, Malkowski B, Walecki J.
    Neuro Endocrinol Lett; 2007 Dec 05; 28(6):789-800. PubMed ID: 18063942
    [Abstract] [Full Text] [Related]

  • 20. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar 05; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.